Search Results for “EC” – Page 578 – media

FDA approves algorithm that predicts sudden patient deaths to help prevent them

Wave Clinical Platform is the work of ExcelMedical and is a system that monitors patients' vital signs, sending alerts that warn of potentially fatal heart attacks or respiratory failure up to six hours before a patient suffers such an event.
- Source: Digital Trends
- 502
- January 16, 2018
FDA healthcare technology New Approvals
FDA approves first treatment for breast cancer with a certain inherited genetic mutation

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.
- Source: finance.yahoo
- 545
- January 15, 2018
breast cancer Lynparza metastasized New Approvals
Alveo Closes $38 Million in Series A Financing to Create Accessible Diagnostics Devices

Alveo Technologies, Inc., ("Alveo" or "the Company") whose mission it is to create affordable and accessible infectious disease diagnostic devices, announced the closing of a $38 million Series A financing raised by Maxim Merchant Capital, a division of Maxim Group LLC. The round was oversubscribed and included existing and new investors. The offering proceeds will be used to advance the optimization and commercialization of Alveo's rapid diagnostic platform for infectious diseases.
- Source: Prnewswire
- 395
- January 15, 2018
infectious diseases Market Views Series
New AI system for lung cancer and heart disease

Artificial intelligence is gradually being adopted by health services to assist medics with the diagnosis of serious diseases. In one new development, scientists in Oxford, U.K. have launched an AI system for heart disease.
- Source: Digital Journal
- 955
- January 15, 2018
AI heart attacks lung cancer Researches
UK Takes Stricter Stance on Human Factors Engineering for Medical Devices

Recent guidance from UK medical device market regulators on human factors engineering (HFE) includes some recommendations that differ from HFE requirements established in Europe, suggesting a more standalone British approach to some areas of device development.
- Source: Emergo
- 583
- January 15, 2018
FDA medical device Policy
China’s Import and Export Report of External Use Otology Drugs

According to the latest statistics of World Health Organization (WHO), the number of people with hearing disabilities in the world has reached 360 million. With the ageing population and the number of hearing-impaired persons increasing year by year, the external otology drugs market shows an increasing trend.
- Source: Ddu
- 41,309
- January 12, 2018
Ddu College otology drugs
NHS Confed orders reports into NHS funding needs

The NHS Confederation has tasked the Institute for Fiscal Studies and the Health Foundation with analysing the funding needs of the UK’s health and care systems over the next 15 years.
- Source: pharmatimes
- 499
- January 12, 2018
health NHS polices
Depression medication initiation may lower oral antidiabetic drug adherence in diabetes

Adults with type 2 diabetes and major depressive disorders who begin using second-generation antipsychotics are more likely to have at least a 10% decline in oral antidiabetic drug use 180 to 365 days after initiation compared with nonusers of second-generation antipsychotics, according to a study.
- Source: Healio
- 625
- January 12, 2018
antipsychotics diabetes Researches
Sex hormone-binding globulin associated with androgen deficiency

Higher levels of sex hormone-binding globulin were associated with androgen deficiency in men, independent of total testosterone level, researchers in Italy reported.
- Source: healio
- 416
- January 12, 2018
androgen deficiency Researches sex hormone
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies

Celgene Corporation (CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.
- Source: finance.yahoo
- 502
- January 12, 2018
Celgene FDA Fedratinib Impact Market Views myelofibrosis

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.